ILC Dover Responds to PPE Shortage: Expedites Manufacturing of New PAPR Hood

ILC Dover, a world leader in the innovative design and production of engineered products employing high-performance flexible materials, announced today that it expedited the regulatory approval and manufacturing processes of a new Powered Air Purifying Respirator (PAPR) hood for healthcare workers attending to patients with COVID-19. Effective today, the new infectious disease hood called Sentinel EZ BioHood™ is available for purchase.

In response to the severe shortage of PPE, ILC Dover expedited the design, development, and manufacture of Sentinel EZ BioHood™. The accelerated process was made possible by the National Institute for Occupational Safety and Health (NIOSH), which stepped up in a major way, expediting their normal regulatory approval process to one week.

Sentinel EZ BioHood™ is NIOSH-approved as a loose-fitting hood designed to work with ILC Dover’s Sentinel XL® blower system. It features an APF of 1,000, and when compared to N-95 masks which offer an APF of 10, Sentinel EZ BioHood™ provides 100x the protection. In further contrast to N-95 masks, Sentinel EZ BioHood™ is supplied with clean filtered air, can be worn comfortably for long periods of time, and provides exceptional visibility.

“The team at ILC Dover, with critical support from NIOSH, has been working tirelessly on Sentinel EZ BioHood™, striving to provide relief to healthcare workers as quickly as possible,” said Fran DiNuzzo, President and CEO at ILC Dover. “A core goal at ILC Dover is to safeguard people from hazardous conditions, so as a company, mobilizing to develop PPE solutions is our responsibility. But as individuals with an inherent desire to help others, working relentlessly to complete this development was an act of passion.”

The hood’s design is intuitive to use, compact to store, allows a stethoscope to be worn simultaneously, and workers do not need to be fit-tested to wear it effectively. Other features include an internal headband, wrap-around clear visor, loose-fitting neck cuff, and lay-flat hood design/2D.

SourceILC Dover

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”